780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hamilton, EP
  • Melero, I
  • Lugowska, I
  • Arance Fernandez, AM
  • Vila Martinez, L
  • Powderly, JD
  • Gutierrez, M
  • Serino, T
  • Mehta, N
  • Shapiro, I
  • Whalen, Katherine
  • Michaelson, J
  • Jones, J
  • Janik, JE
  • Moreno Garcia, V

publication date

  • September 2022